Difference between revisions of "Talk:Tay-Sachs Disease 2012"

From Bioinformatikpedia
(Feedback)
Line 17: Line 17:
 
* 5.2 Catalytic activity: It is hard to understand why the inhibitor provides information about potential residues that bind the true substrate GM2. Your pymol picture looks quite nice, but it is not obvious why you are highlighting the inhibitor instead of GM2. Your reference to the original publication is of course helpful.
 
* 5.2 Catalytic activity: It is hard to understand why the inhibitor provides information about potential residues that bind the true substrate GM2. Your pymol picture looks quite nice, but it is not obvious why you are highlighting the inhibitor instead of GM2. Your reference to the original publication is of course helpful.
 
* 7 Mutations: Listing all mutations is actually not necessary.
 
* 7 Mutations: Listing all mutations is actually not necessary.
  +
  +
  +
Christof, Guokun

Revision as of 23:26, 23 April 2012

Feedback

The text is well organized, with comprehensive information about the disease. Scientific terms are used appropriately and the content is comprehensible. In general, using short sentences instead of subordinate clauses would make the text even better to understand. All topics are cited extensively which allows the reader to easily retrieve further information.

Format

  • For table 1 in section "Distinction to other sphingolipidoses ", the explanation to the columns could be in a separate paragraph. Adding visible table border might look better (get help here [1]).
  • Using 'Biochemical basis' instead of 'Biochemical Basis' would make the captions more consistent.
  • You might make 'Distinction to other sphingolipidoses' a subtopic of 'Biochemical basis' to reduce the number of main topics (currently 11).

Content

  • 1 Summary: Here it is not clear that GM2 is the substrate that can not be degraded.
  • Adding an image of the "Cherry-red" or some pictures of the symptoms might give the readers an intuitive impression of the disease.
  • In section "Prevalence ", maybe add some statistic about the disease frequency of the Ashkenazi Jews and eastern Quebec French Canadians population.
  • In section "Distinction to other sphingolipidoses", a short explanation of "sphingolipidoses" might be helpful.
  • 5.2 Catalytic activity: It is hard to understand why the inhibitor provides information about potential residues that bind the true substrate GM2. Your pymol picture looks quite nice, but it is not obvious why you are highlighting the inhibitor instead of GM2. Your reference to the original publication is of course helpful.
  • 7 Mutations: Listing all mutations is actually not necessary.


Christof, Guokun